Affiris GmbH of Vienna, Austria said its Alzheimer's vaccine entered clinical trials, triggering a key milestone in its Euro 8.5 million venture capital finance agreement with Munich-based MIG-Fonds in April 2006.
Up to 24 Alzheimer's patients are to be vaccinated, with the aim of this initial phase I trial being to demonstrate safety. Patients will be vaccinated four times over a period of three months, and the safety and suitability of the vaccine will be analysed over six months.